Clinical Trials Logo

Clinical Trial Summary

According to Diabetes Canada ("DC"), in 2015, the estimated prevalence of prediabetes in Canada (>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada . There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.


Clinical Trial Description

INTRODUCTION: LMC Healthcare, in collaboration with Diabetes Canada and INTERVENT International, is inviting participants to be part of a new program called the Canadian Diabetes Prevention Program ("CDPP") aimed at reducing the risk of developing Type 2 Diabetes. Participants can join the CDPP if participants have been diagnosed with prediabetes or participants score 33 or above on the CANRISK Questionnaire (a validated tool used to assess diabetes risk). Information collected from the CDPP will be used for research purposes. BACKGROUND / RATIONALE: According to Diabetes Canada ("DC"), in 2015, the estimated number of people with prediabetes in Canada (>20 years of age) was 5.7 million people (22.1%). Prediabetes can be defined as people with a blood sugar level that is higher than normal but not high enough to be diagnosed with diabetes; these people are at high risk for developing diabetes. This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently type 2 diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada. There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes. The proposed intervention would target participants who are identified as "at risk" using the Canadian Diabetes Risk Assessment Questionnaire (CANRISK) or those participants who have been diagnosed with prediabetes based on blood work. PURPOSE/OBJECTIVE: To reduce the risk of developing Type 2 Diabetes Mellitus by taking part in a 12-month lifestyle intervention program. A select group of participants, 452 participants, will have a follow up at 18 months to assess a post-study progression. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05784220
Study type Interventional
Source LMC Diabetes & Endocrinology Ltd.
Contact
Status Active, not recruiting
Phase N/A
Start date June 21, 2019
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Completed NCT05915338 - Training on Using ıInsulin in Patients With Type 2 Diabetes
Not yet recruiting NCT04998461 - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Not yet recruiting NCT04880005 - Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid N/A
Recruiting NCT05365529 - Time-Restricted Eating for Type II Diabetes: TRE-T2D N/A
Recruiting NCT03958591 - Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification Phase 4
Completed NCT05284071 - Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation N/A
Recruiting NCT05501093 - Diabetes Reversal and the Subgingival Microbiota
Active, not recruiting NCT04286555 - Dietary Approaches to Stop Hypertension for Diabetes N/A
Completed NCT05076656 - Epigenetic and Microbiota Modifications Early Phase 1
Completed NCT04423302 - Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT) N/A
Completed NCT05928637 - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150 Phase 1
Active, not recruiting NCT04660630 - A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias N/A
Recruiting NCT03435328 - Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients N/A
Recruiting NCT04447859 - 16-week Flexible vs. 8-week Semaglutide Titration Phase 3
Not yet recruiting NCT03968354 - NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Terminated NCT04819256 - Primary Care Based Integrated Community Care Team Intervention N/A
Recruiting NCT05629221 - Organisational Models Supported by Technology for the Management of Diabetic Disease and Its Complications in a Diabetic Clinic Setting. A Randomised Controlled Trial Targeting Type 2 Diabetes Individuals With Non-ideal Glycemic Values N/A
Completed NCT05260983 - Acceptance and Commitment Therapy Principles for Diabetes Prevention N/A